Artrya Ltd
ASX:AYA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (25.5), the stock would be worth AU$-3.77 (191% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -28.1 | AU$4.16 |
0%
|
| Industry Average | 25.5 | AU$-3.77 |
-191%
|
| Country Average | 16.5 | AU$-2.45 |
-159%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
AU$416.6m
|
/ |
Jan 2026
AU$-20.7m
|
= |
|
|
AU$416.6m
|
/ |
Jun 2026
AU$-12.5m
|
= |
|
|
AU$416.6m
|
/ |
Jun 2027
AU$18.8m
|
= |
|
|
AU$416.6m
|
/ |
Jun 2028
AU$38.1m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
A
|
Artrya Ltd
ASX:AYA
|
657.6m AUD | -28.1 | -33.5 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 21.9 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
26.8B USD | 20.4 | 29.5 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.9B AUD | 77.5 | 62.6 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 10.2 | 20.8 | |
| SE |
|
Sectra AB
STO:SECT B
|
51.8B SEK | -133.5 | 96.4 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.9B USD | 15.2 | 42.3 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 14.9 | 18.8 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | 267.9 | -328 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
18.6B CNY | -118 | -60.4 | |
| US |
H
|
Heartflow Inc
NASDAQ:HTFL
|
2.8B USD | 0 | 0 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 16.5 |
| 70th Percentile | 24.5 |
| Max | 6 797.5 |
Other Multiples
Artrya Ltd
Glance View
Artrya Ltd. develops the Salix suite of products to address coronary artery disease (CAD). The company is headquartered in Perth, Western Australia. The company went IPO on 2021-11-26. The firm is focused on operating diagnostic imaging center. The company is primarily engaged in providing powered image-analysis software for coronary artery disease. Its non-invasive solution, Salix uses artificial intelligence (AI) to produce a 3D image and report that provides an accurate detection of coronary artery disease, including the presence of vulnerable plaque. Salix offers precision medicine for cardiac care. The company enables clinicians to triage patients and identify individuals at high risk of heart attack. The firm's cardiac-health report provides diagnostic support to radiologists and cardiologists.
